Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Inhibitor Therapeutics, Inc. (HPPI)
|
Add to portfolio |
|
|
|
| Price: |
$0.08
| | Metrics |
| OS: |
172.0
|
M
| |
155
|
% ROE
|
| Market cap: |
$12.9
|
M
| |
2124
|
% ROIC
|
|
Net cash:
|
$10.1
|
M
| |
$0.06
|
per share
|
|
EV:
|
$2.8
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
$11.1
|
M
| |
0.3
|
x EV/EBITDA
|
|
EBIT
|
$11.1
|
M
| |
0.3
|
x EV/EBIT
|
| EPS |
$0.03
| |
2.9
|
x P/E
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 13.6 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Revenue growth | 32612.1% | | | | | | | |
| Cost of goods sold | 0.0 | 0.0 | -1.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 13.6 | 0.0 | 1.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross margin | 100.0% | 0.0% | | | | | | |
| Selling, general and administrative | | | | | | | | |
| Research and development | 0.0 | 0.0 | 0.2 | 1.2 | 2.6 | 2.2 | 2.6 | 1.7 |
| General and administrative | 0.7 | 0.3 | 0.9 | 1.5 | 1.9 | 2.9 | 4.4 | 2.3 |
| EBIT | 12.3 | -0.3 | -1.1 | -2.7 | -4.6 | -5.1 | -7.0 | -3.9 |
| EBIT margin | 90.3% | -782.2% | | | | | | |
| Pre-tax income | 12.2 | -0.3 | -1.1 | -2.7 | -4.6 | -5.1 | -7.0 | -3.9 |
| Income taxes | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.5% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | 11.9 | -0.5 | -1.3 | -2.9 | -4.7 | -5.1 | -7.0 | -3.9 |
| Net margin | 87.6% | -1198.6% | | | | | | |
| |
| Diluted EPS | $0.03 | $0.00 | $0.00 | ($0.01) | ($0.01) | ($0.01) | ($0.02) | ($0.02) |
| Shares outstanding (diluted) | 367.8 | 376.2 | 371.9 | 370.4 | 369.8 | 366.6 | 288.8 | 232.6 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|